Bioprinted organs soon could revolutionize clinical trials, transplantation, and regenerative medicine. However, several technical hurdles must be navigated for biopharmaceutical companies to successfully harness and commercialize three-dimensional (3D) printing for such purposes.
In this BioProcess International interview, Lev Gerlovin, Andrew Thomson, and Jack Vailas, along with Bill Whitford of GE Healthcare Life Sciences, discuss persistent printing problems and analyze promising solutions raised by Chris Lo in a recent GlobalData: Medical Technology report (November 2019) entitled “The Long Road to Reliable Organ Printing.”
To read the interview, download the PDF below.
From spreadsheet to strategy: How leading pharma companies transform annual brand planning into competitive advantage
Insight as your ABP backbone Annual Brand Planning (ABP) should not feel like a reinvention exercise every year, particularly for established brands. Instead,...